|
|
|
|
|||||
|
|
|
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Entero Therapeutics, Inc. is included in them.
Entero Therapeutics, Inc. (NASDAQ:ENTO) is a clinical-stage biopharmaceutical company developing targeted, non-systemic therapies for gastrointestinal disorders, including celiac disease, gastroparesis, and pancreatic insufficiency. The company has recently drawn attention as a biotech penny stock due to key developments in September 2025.
A major change in leadership marked the month, with interim CEO Richard Joel Paolone replaced by Jason D. Sawyer, effective September 9. Sawyer brings significant venture investment experience, signaling a potential strategic focus on new funding and partnership opportunities to support the company’s growth and pipeline advancement.
Entero Therapeutics, Inc. (NASDAQ:ENTO) also navigated the effects of its August 2025 1-for-3 reverse stock split, implemented to maintain Nasdaq compliance and protect its public listing. While necessary, the split contributed to market volatility and investor caution amid ongoing financial and governance scrutiny.
On the financing front, Entero Therapeutics, Inc. (NASDAQ:ENTO) completed a $3 million private placement through warrant offerings, enhancing liquidity for working capital and ongoing research. Key pipeline initiatives include Adrulipase, a recombinant lipase therapy for cystic fibrosis and chronic pancreatitis, as well as investigational treatments for celiac disease.
While we acknowledge the potential of ENTO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
| Oct-16 | |
| Oct-14 | |
| Oct-14 | |
| Oct-01 | |
| Oct-01 | |
| Sep-23 | |
| Aug-14 | |
| Aug-11 | |
| Aug-11 | |
| Mar-24 | |
| Feb-14 | |
| Feb-07 | |
| Nov-14 | |
| Nov-13 | |
| Sep-10 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite